Cardica (CRDC) Reports In-Line Q3 EPS

Cardica (NASDAQ: CRDC) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $600 thousand versus the consensus estimate of $540 thousand.

"At the end of the third quarter of fiscal 2015, we reintroduced a modified MicroCutter XCHANGE® 30 suitable for use with our white cartridges only. This controlled commercial release is focusing primarily on customers in Europe where our regulatory clearance is sufficiently broad," said Bernard A. Hausen, M.D., Ph.D., president and CEO of Cardica. "We recently submitted a 510(k) application to the U.S. Food and Drug Administration to expand the indications for use to include vascular structures, similar to the indications in Europe. In parallel, we continue to make good progress in our redesign of the XCHANGE 30 to be compatible for both white and blue cartridges, with initial feasibility evaluation in humans scheduled to begin in the second half of calendar 2015."

For earnings history and earnings-related data on Cardica (CRDC) click here.

You May Also Be Interested In

• Honeywell (HON) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY Guidance
• Teck Resources (TECK) Misses Q1 EPS by 15c; reaffirms FY guidance
• Willis Towers Watson (WTW) Tops Q1 EPS by 4c, provides guidance